NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 6, 2019

Primary Completion Date

October 12, 2023

Study Completion Date

February 20, 2024

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Gemtuzumab Ozogamicin

Gemtuzumab Ozogamicin 3mg/m\^2, Days 1,4,7

DRUG

Venetoclax

Venetoclax, 100,200,400, or 600mg Daily Dose

Trial Locations (4)

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

University of Michigan Health System, Ann Arbor

Univeristy of Illinois, Chicago

University of Nebraska Medical Center, Omaha